Privosegtor

Phase 3

OOculis

Privosegtor is one of 9 therapeutic programs targeting Optic Neuritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Optic NeuritisRecruiting

Optic NeuritisPhase 3

Recruiting

Competition

Competitive Landscape

8 competitors in Optic Neuritis

#DrugCompanyPhaseTrials

Calciferol

Jazz Pharmaceuticals

Approved

—2

Decadron

AAspen Global Incorporated

Approved

—3

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Medrol

3 5

Vyvgart

Argenx

Phase 2

1 6

Tavist

HHALEON

Phase 2

1 7

Privosegtor

OOculis

Phase 3

1 8

Radicava

Shionogi

Preclinical

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Optic Neuritis

NCT07623668

Clinical

Trials by Indication[1]

Optic Neuritis1 trial

A Randomized, Double-masked, Placebo-controlled Study Assessing the Efficacy and Safety of Privosegtor (OCS-05) in Patients With Optic Neuritis (ON)

Recruiting·OOculis·Phase 3·NCT07623668·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Privosegtor. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Privosegtor. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Oculis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: OOculis

Privosegtor

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Optic Neuritis1 trial

References

Drug Info

Quick Facts

Related News